Fingolimod Hydrochloride

Relapsing Remitting Multiple Sclerosis, Multiple Sclerosis, Carcinoma in Situ + 2 more
Treatment
20 Active Studies for Fingolimod Hydrochloride

What is Fingolimod Hydrochloride

FingolimodThe Generic name of this drug
Treatment SummaryFingolimod is a medication used to treat Multiple Sclerosis (MS), a chronic inflammatory disorder that can cause physical, cognitive, and neurological impairments. It was created by Novartis and approved by the FDA in 2010. It is currently being tested to see if it can help treat COVID-19, the disease caused by SARS-CoV-2 virus, with Phase 2 clinical trials expected to be completed in July 2020.
Gilenyais the brand name
image of different drug pills on a surface
Fingolimod Hydrochloride Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Gilenya
Fingolimod
2010
16

Effectiveness

How Fingolimod Hydrochloride Affects PatientsFingolimod is used to treat multiple sclerosis, and may also help reduce lung inflammation in people with COVID-19. However, taking it may cause a decrease in heart rate and prolong the QT interval.
How Fingolimod Hydrochloride works in the bodyFingolimod is a drug that helps regulate inflammation in people with Multiple Sclerosis (MS). It works by binding to certain receptors in the body, including the cardiovascular, immune, and central nervous systems. When bound, it stops lymphocytes from leaving the lymph nodes and entering the circulation. This reduces the inflammation associated with MS. It's also sometimes used to prevent Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19.

When to interrupt dosage

The measure of Fingolimod Hydrochloride is contingent upon the diagnosed ailment, including Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis (RRMS) and Alternative Treatment. The magnitude of dosage is contingent upon the method of administration (e.g. Capsule - Oral or Capsule) presented in the table below.
Condition
Dosage
Administration
Relapsing Remitting Multiple Sclerosis
, 0.5 mg, 0.25 mg
Capsule - Oral, , Oral, Capsule
Carcinoma in Situ
, 0.5 mg, 0.25 mg
Capsule - Oral, , Oral, Capsule
Multiple Sclerosis
, 0.5 mg, 0.25 mg
Capsule - Oral, , Oral, Capsule
Multiple Sclerosis
, 0.5 mg, 0.25 mg
Capsule - Oral, , Oral, Capsule
Alternative Treatment
, 0.5 mg, 0.25 mg
Capsule - Oral, , Oral, Capsule

Warnings

Fingolimod Hydrochloride has fifteen contraindications, so its use should be avoided in circumstances involving any of the conditions in the following table.Fingolimod Hydrochloride Contraindications
Condition
Risk Level
Notes
Atrioventricular Block
Do Not Combine
Atrioventricular Block
Do Not Combine
Stroke
Do Not Combine
Angina, Unstable
Do Not Combine
Transient Ischemic Attack (TIA)
Do Not Combine
Atrioventricular Block
Do Not Combine
Heart Decompensation
Do Not Combine
Sick Sinus Syndrome
Do Not Combine
Heart failure
Do Not Combine
Pulse Frequency
Do Not Combine
Atrioventricular Block
Do Not Combine
Pulse Frequency
Do Not Combine
Heart Attack
Do Not Combine
Pulse Frequency
Do Not Combine
Heart failure
Do Not Combine
There are 20 known major drug interactions with Fingolimod Hydrochloride.
Common Fingolimod Hydrochloride Drug Interactions
Drug Name
Risk Level
Description
Adenovirus type 7 vaccine live
Major
The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Fingolimod.
Ajmaline
Major
Fingolimod may increase the arrhythmogenic activities of Ajmaline.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Fingolimod.
Amiodarone
Major
Fingolimod may increase the arrhythmogenic activities of Amiodarone.
Anthrax vaccine
Major
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Fingolimod.
Fingolimod Hydrochloride Toxicity & Overdose RiskThe lowest toxic dose of fingolimod in rats is between 300 - 600 mg/kg. In one case report, an intentional overdose of 14mg of fingolimod and 2g of phenoxymethylpenicillin caused low blood pressure and a slow heartbeat, both of which were reversed by taking atropine. As fingolimod has been linked to heart problems, it is likely that an overdose could cause similar issues such as a slow heartbeat and blockage of the heart's electrical signals.
image of a doctor in a lab doing drug, clinical research

Fingolimod Hydrochloride Novel Uses: Which Conditions Have a Clinical Trial Featuring Fingolimod Hydrochloride?

At present, 44 active studies are being conducted to assess the effectiveness of Fingolimod Hydrochloride in treating active Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis and Carcinoma in Situ.
Condition
Clinical Trials
Trial Phases
Multiple Sclerosis
12 Actively Recruiting
Phase 3, Phase 4, Phase 2
Relapsing Remitting Multiple Sclerosis
14 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Phase 4, Early Phase 1
Alternative Treatment
0 Actively Recruiting
Carcinoma in Situ
3 Actively Recruiting
Not Applicable, Phase 4
Multiple Sclerosis
0 Actively Recruiting

Fingolimod Hydrochloride Reviews: What are patients saying about Fingolimod Hydrochloride?

5Patient Review
6/17/2012
Fingolimod Hydrochloride for Multiple Sclerosis Symptoms Return then Become Less Severe
This treatment has been wonderful. I'm unable to take any other treatments, so this really was a blessing. In the two years that I've been taking it, I've only had one flare-up compared to six to ten per year previously. Additionally, I haven't felt this good in a long time.
5Patient Review
12/21/2010
Fingolimod Hydrochloride for Multiple Sclerosis Symptoms Return then Become Less Severe
I've been in a clinical trial for this medicine for 3+ years and it's going great! I've had mild side effects and excellent results. No new MS attacks in over 3 years.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about fingolimod hydrochloride

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is fingolimod used for MS?

"Fingolimod is an immunotherapeutic drug that is used to target the sphingosine-1-phosphate receptor. It is a widely used medication for relapsing-remitting multiple sclerosis (MS)."

Answered by AI

What is fingolimod used for?

"Fingolimod is used to help manage relapsing-remitting forms of multiple sclerosis (where symptoms flare up from time to time) in adults and children 10 years and older. It may help prevent episodes of symptoms and slow the progression of disability caused by MS."

Answered by AI

What is the brand name for fingolimod?

"Gilenya is a prescription medicine that is used to treat the symptoms of Multiple sclerosis. It is an immunomodulator and sphingosine 1-phosphate receptor modulator that can be used alone or with other medications."

Answered by AI

What is the mechanism of action of fingolimod?

"Fingolimod works by binding to and activating the S1P1 receptor, which is found on the surface of lymphocytes. This prevents the lymphocytes from leaving the lymph nodes, and reduces the amount of autoaggressive lymphocytes that can enter the central nervous system."

Answered by AI

Clinical Trials for Fingolimod Hydrochloride

Image of University of Maryland, Baltimore in Baltimore, United States.

Ublituximab for Multiple Sclerosis

18 - 65
All Sexes
Baltimore, MD
The purpose of the research study is to explore new retinal imaging biomarkers of immune cell activity in MS during use of ublituximab (Briumvi) treatment. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. This study will evaluate the efficacy of ublituximab to modulate MS pathology in a new manner. In order to assess this new biomarker, a specialized optical coherence tomography (OCT) scan will be performed at enrollment into the study and at 2 other timepoints throughout the study. Subjects asked to take part in this study should have been diagnosed with relapsing multiple sclerosis (MS) and have recently been advised to start the medication ublituximab (Briumvi) or are currently on another medication for the treatment of their MS. We plan to enroll 30 patients into this study. Fifteen (15) patients with Relapsing Remitting Multiple Sclerosis (RRMS) who are being initiated on B-cell depletion therapy by their treating physician at the University of Maryland Center for MS Treatment and Research will be offered enrollment into this study. Additionally, 15 age/sex matched patients with stable RRMS who are not undergoing any change in treatment and are not currently on B-cell depleting therapies will be enrolled as control subjects.
Waitlist Available
Has No Placebo
University of Maryland, BaltimoreDaniel Harrison, MDTG Therapeutics, Inc.
Have you considered Fingolimod Hydrochloride clinical trials? We made a collection of clinical trials featuring Fingolimod Hydrochloride, we think they might fit your search criteria.Go to Trials
Image of Clinical Translational Research Center at CU Anschutz in Aurora, United States.

Vagus Nerve Stimulation for Multiple Sclerosis

18 - 65
All Sexes
Aurora, CO
The goal of this clinical trial is to learn if stimulating the vagus nerve in combination with a motor task in people with multiple sclerosis can improve motor function. The main questions it aims to answer are: * Is stimulating the vagus nerve safe and feasible after demyelinating episodes? * Does a paired motor task with vagus nerve stimulation improve motor function with someone who has multiple sclerosis? Researchers will compare active vagus nerve stimulation to a sham stimulation to see if the paired vagus nerve stimulation can improve motor control. Participants will: * Come in for study visits over a six month period. Study visits are three times weekly for the first month, then single follow up visits at two, three, and six months. * During study visits, participants will complete 30 minutes of the paired vagus nerve stimulation with a motor task, specifically the grooved peg test. * At various timepoints in the study, motor and disability tests will be administered to see if there are any changes in motor control for that participants. These tests include the timed 25 foot walk test, expanded disability scale, the upper extremity portion of the Fugl-Meyer Assessment, and the Multiple Sclerosis Impact Scale - 29.
Recruiting
1 Prior Treatment
Clinical Translational Research Center at CU AnschutzJeffrey Bennett, MD
Image of Georgia State University in Atlanta, United States.

Ublituximab for Multiple Sclerosis

18 - 55
All Sexes
Atlanta, GA
The purpose of this study is to test if ublituximab changes walking functions and fall risk in people with relapsing multiple sclerosis (RMS). Twenty-five qualified people with RMS will undergo a 48-week ublituximab treatment. Before, 24 weeks into, and after the treatment, their ambulatory function, disability status, and cognition will be assessed. Additionally, they will experience large-scale slip perturbations on a treadmill under the protection of a safety harness at the last assessment. The outcome measures will be compared across the assessments to examine the effects of ublituximab on improving their walking function, disability status, cognition, and the responses to the unexpected slip perturbation.
Phase < 1
Waitlist Available
Georgia State University (+1 Sites)
Have you considered Fingolimod Hydrochloride clinical trials? We made a collection of clinical trials featuring Fingolimod Hydrochloride, we think they might fit your search criteria.Go to Trials
Image of Shirley Ryan AbilityLab in Chicago, United States.

Intermittent Hypoxia for Multiple Sclerosis

18 - 75
All Sexes
Chicago, IL
This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS). This intervention with low levels of oxygen is called Acute Intermittent Hypoxia (AIH), the levels of oxygen experienced are similar to breathing the air on a tall mountain, for less than 1 minute at a time. Previous studies have shown that AIH is a safe and effective way to increase strength in persons with MS. Here the investigators aim to look at brain activation and ankle strength before and after AIH to gain a better understanding of how the AIH may improve strength in those persons with MS.
Recruiting
Has No Placebo
Shirley Ryan AbilityLabMilap Sandhu, Pt, PhD
Have you considered Fingolimod Hydrochloride clinical trials? We made a collection of clinical trials featuring Fingolimod Hydrochloride, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security